Drug Trial Radar · NCT04898751
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Last checked: Nov 20, 2026Latest source record: May 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,214
Actual
Start
Jan 1, 2008
Primary completion
Aug 31, 2020
Study completion Aug 31, 2020
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 24, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to appear. This study examines the appearance of cirAEs within the World Health Organization (WHO) pharmacovigilance database, VigiBase.
Conditions
- Cutaneous Toxicity From ICI Therapy
Interventions
Immune checkpoint inhibitor (ICI)Drug
Immune checkpoint inhibitors included were targeting either PD-1, PD-L1 or CTLA-4, and had received FDA approval at the time of study (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), and Cemiplimab (L01XC33).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cutaneous toxicity of ICIsTime frame: From 01/01/2008 to 08/31/2020
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sidney Kimmel Comprehensive Care Center
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.